国内外最新银屑病诊疗指南解读——疾病严重程度评估及生物制剂治疗

Interpretation of the latest guidelines for the diagnosis and the treatment of psoriasis at home and abroad:the assessment of disease severity and the treatment with biological agents

银屑病生物制剂的问世推动了各国指南的制定和更新。本文就银屑病疾病严重程度评估和生物制剂应用,解读了具有权威性的中国、美国、欧洲、亚洲、英国及法国银屑病诊疗指南和银屑病生物制剂诊疗指南,分析和归纳了各国指南的基本用药原则和差异,以帮助临床医生更好选择和应用生物制剂,避免出现继发失效和严重不良事件。

The advent of biologics for psoriasis has driven the development and update of national guidelines.The purpose of this article is to explain the authoritative guidelines for the treatment of psoriasis in China,the United States,Europe,Asia,the United Kingdom,and France,and the guidelines for the treatment of psoriasis with biological agents,with respect to the evaluation of the severity of psoriasis and the application of biological agents.Basic principles and nuances of these guidelines are summarized in order to assist clinicians making decision of selection and application of biologics,avoiding secondary failure and severe adverse events.